NEW YORK (GenomeWeb) – ProZyme and BiOptic said on Thursday they are collaborating to develop and commercialize an integrated system for high-throughput glycoanalysis.
The collaboration will extend ProZyme's portfolio of glycobiology products while leveraging BiOptic's suite of capillary gel electrophoresis instruments, they said. Prozyme will use BiOptic's CGE platforms with fluorescence detection and replaceable gel-cartridge design for the rapid separation and detection of labeled glycans.
ProZyme's chemistry will be used to prepare enzymatically released and fluorescently labeled glycans on the front end of the Gly-Q system, while customized software and ProZyme N-glycan reference standards will simplify data analysis on the back end.
ProZyme will exclusively market the system worldwide for N-glycan sample preparation, separation, and analysis. The partners plan to commercialize the Gly-Q system for applications such as biotherapeutic cell line development, they said.
Financial and other terms of the deal were not disclosed.
ProZyme is based in Hayward, California and manufactures bioreagents for glycobiology. Taiwan-based BiOptic manufactures CGE instruments for DNA analysis.